Targeting VE-PTP phosphatase protects the kidney from diabetic injury

Isabel A. Carota, Yael Kenig-Kozlovsky, Tuncer Onay, Rizaldy P Scott, Benjamin R. Thomson, Tomokazu Souma, Christina S. Bartlett, Yanyang Li, Daniele Procissi, Veronica Ramirez, Shinji Yamaguchi, Antoine Tarjus, Christine E. Tanna, Chengjin Li, Vera Eremina, Dietmar Vestweber, Sunday S. Oladipupo, Matthew D. Breyer, Susan E Quaggin*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Diabetic nephropathy is a leading cause of end-stage kidney failure. Reduced angiopoietin-TIE2 receptor tyrosine kinase signaling in the vasculature leads to increased vascular permeability, inflammation, and endothelial cell loss and is associated with the development of diabetic complications. Here, we identified a mechanism to explain how TIE2 signaling is attenuated in diabetic animals. Expression of vascular endothelial protein tyrosine phosphatase VE-PTP (also known as PTPRB), which dephosphorylates TIE2, is robustly up-regulated in the renal microvasculature of diabetic rodents, thereby reducing TIE2 activity. Increased VE-PTP expression was dependent on hypoxia-inducible factor transcriptional activity in vivo. Genetic deletion of VE-PTP restored TIE2 activity independent of ligand availability and protected kidney structure and function in a mouse model of severe diabetic nephropathy. Mechanistically, inhibition of VE-PTP activated endothelial nitric oxide synthase and led to nuclear exclusion of the FOXO1 transcription factor, reducing expression of pro-inflammatory and pro-fibrotic gene targets. In sum, we identify inhibition of VE-PTP as a promising therapeutic target to protect the kidney from diabetic injury.

Original languageEnglish (US)
Pages (from-to)936-949
Number of pages14
JournalJournal of Experimental Medicine
Volume216
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Class 3 Receptor-Like Protein Tyrosine Phosphatases
Diabetic Nephropathies
Kidney
Wounds and Injuries
TIE-2 Receptor
Angiopoietins
Nitric Oxide Synthase Type III
Capillary Permeability
Diabetes Complications
Microvessels
Renal Insufficiency
Rodentia
Transcription Factors
Endothelial Cells
Ligands
Inflammation
Genes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Carota, Isabel A. ; Kenig-Kozlovsky, Yael ; Onay, Tuncer ; Scott, Rizaldy P ; Thomson, Benjamin R. ; Souma, Tomokazu ; Bartlett, Christina S. ; Li, Yanyang ; Procissi, Daniele ; Ramirez, Veronica ; Yamaguchi, Shinji ; Tarjus, Antoine ; Tanna, Christine E. ; Li, Chengjin ; Eremina, Vera ; Vestweber, Dietmar ; Oladipupo, Sunday S. ; Breyer, Matthew D. ; Quaggin, Susan E. / Targeting VE-PTP phosphatase protects the kidney from diabetic injury. In: Journal of Experimental Medicine. 2019 ; Vol. 216, No. 4. pp. 936-949.
@article{4860610da8d54353919f55d01dcbb53a,
title = "Targeting VE-PTP phosphatase protects the kidney from diabetic injury",
abstract = "Diabetic nephropathy is a leading cause of end-stage kidney failure. Reduced angiopoietin-TIE2 receptor tyrosine kinase signaling in the vasculature leads to increased vascular permeability, inflammation, and endothelial cell loss and is associated with the development of diabetic complications. Here, we identified a mechanism to explain how TIE2 signaling is attenuated in diabetic animals. Expression of vascular endothelial protein tyrosine phosphatase VE-PTP (also known as PTPRB), which dephosphorylates TIE2, is robustly up-regulated in the renal microvasculature of diabetic rodents, thereby reducing TIE2 activity. Increased VE-PTP expression was dependent on hypoxia-inducible factor transcriptional activity in vivo. Genetic deletion of VE-PTP restored TIE2 activity independent of ligand availability and protected kidney structure and function in a mouse model of severe diabetic nephropathy. Mechanistically, inhibition of VE-PTP activated endothelial nitric oxide synthase and led to nuclear exclusion of the FOXO1 transcription factor, reducing expression of pro-inflammatory and pro-fibrotic gene targets. In sum, we identify inhibition of VE-PTP as a promising therapeutic target to protect the kidney from diabetic injury.",
author = "Carota, {Isabel A.} and Yael Kenig-Kozlovsky and Tuncer Onay and Scott, {Rizaldy P} and Thomson, {Benjamin R.} and Tomokazu Souma and Bartlett, {Christina S.} and Yanyang Li and Daniele Procissi and Veronica Ramirez and Shinji Yamaguchi and Antoine Tarjus and Tanna, {Christine E.} and Chengjin Li and Vera Eremina and Dietmar Vestweber and Oladipupo, {Sunday S.} and Breyer, {Matthew D.} and Quaggin, {Susan E}",
year = "2019",
month = "4",
day = "1",
doi = "10.1084/jem.20180009",
language = "English (US)",
volume = "216",
pages = "936--949",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "4",

}

Carota, IA, Kenig-Kozlovsky, Y, Onay, T, Scott, RP, Thomson, BR, Souma, T, Bartlett, CS, Li, Y, Procissi, D, Ramirez, V, Yamaguchi, S, Tarjus, A, Tanna, CE, Li, C, Eremina, V, Vestweber, D, Oladipupo, SS, Breyer, MD & Quaggin, SE 2019, 'Targeting VE-PTP phosphatase protects the kidney from diabetic injury', Journal of Experimental Medicine, vol. 216, no. 4, pp. 936-949. https://doi.org/10.1084/jem.20180009

Targeting VE-PTP phosphatase protects the kidney from diabetic injury. / Carota, Isabel A.; Kenig-Kozlovsky, Yael; Onay, Tuncer; Scott, Rizaldy P; Thomson, Benjamin R.; Souma, Tomokazu; Bartlett, Christina S.; Li, Yanyang; Procissi, Daniele; Ramirez, Veronica; Yamaguchi, Shinji; Tarjus, Antoine; Tanna, Christine E.; Li, Chengjin; Eremina, Vera; Vestweber, Dietmar; Oladipupo, Sunday S.; Breyer, Matthew D.; Quaggin, Susan E.

In: Journal of Experimental Medicine, Vol. 216, No. 4, 01.04.2019, p. 936-949.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting VE-PTP phosphatase protects the kidney from diabetic injury

AU - Carota, Isabel A.

AU - Kenig-Kozlovsky, Yael

AU - Onay, Tuncer

AU - Scott, Rizaldy P

AU - Thomson, Benjamin R.

AU - Souma, Tomokazu

AU - Bartlett, Christina S.

AU - Li, Yanyang

AU - Procissi, Daniele

AU - Ramirez, Veronica

AU - Yamaguchi, Shinji

AU - Tarjus, Antoine

AU - Tanna, Christine E.

AU - Li, Chengjin

AU - Eremina, Vera

AU - Vestweber, Dietmar

AU - Oladipupo, Sunday S.

AU - Breyer, Matthew D.

AU - Quaggin, Susan E

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Diabetic nephropathy is a leading cause of end-stage kidney failure. Reduced angiopoietin-TIE2 receptor tyrosine kinase signaling in the vasculature leads to increased vascular permeability, inflammation, and endothelial cell loss and is associated with the development of diabetic complications. Here, we identified a mechanism to explain how TIE2 signaling is attenuated in diabetic animals. Expression of vascular endothelial protein tyrosine phosphatase VE-PTP (also known as PTPRB), which dephosphorylates TIE2, is robustly up-regulated in the renal microvasculature of diabetic rodents, thereby reducing TIE2 activity. Increased VE-PTP expression was dependent on hypoxia-inducible factor transcriptional activity in vivo. Genetic deletion of VE-PTP restored TIE2 activity independent of ligand availability and protected kidney structure and function in a mouse model of severe diabetic nephropathy. Mechanistically, inhibition of VE-PTP activated endothelial nitric oxide synthase and led to nuclear exclusion of the FOXO1 transcription factor, reducing expression of pro-inflammatory and pro-fibrotic gene targets. In sum, we identify inhibition of VE-PTP as a promising therapeutic target to protect the kidney from diabetic injury.

AB - Diabetic nephropathy is a leading cause of end-stage kidney failure. Reduced angiopoietin-TIE2 receptor tyrosine kinase signaling in the vasculature leads to increased vascular permeability, inflammation, and endothelial cell loss and is associated with the development of diabetic complications. Here, we identified a mechanism to explain how TIE2 signaling is attenuated in diabetic animals. Expression of vascular endothelial protein tyrosine phosphatase VE-PTP (also known as PTPRB), which dephosphorylates TIE2, is robustly up-regulated in the renal microvasculature of diabetic rodents, thereby reducing TIE2 activity. Increased VE-PTP expression was dependent on hypoxia-inducible factor transcriptional activity in vivo. Genetic deletion of VE-PTP restored TIE2 activity independent of ligand availability and protected kidney structure and function in a mouse model of severe diabetic nephropathy. Mechanistically, inhibition of VE-PTP activated endothelial nitric oxide synthase and led to nuclear exclusion of the FOXO1 transcription factor, reducing expression of pro-inflammatory and pro-fibrotic gene targets. In sum, we identify inhibition of VE-PTP as a promising therapeutic target to protect the kidney from diabetic injury.

UR - http://www.scopus.com/inward/record.url?scp=85063755950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063755950&partnerID=8YFLogxK

U2 - 10.1084/jem.20180009

DO - 10.1084/jem.20180009

M3 - Article

VL - 216

SP - 936

EP - 949

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 4

ER -